Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Efficacy and the Safety of Flumatinib in Treatment of CML-CP Patients With Ph+ Post Imatinib Failure

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT04677439
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:38:45.418956+00:00
Published At
2022-03-16T00:00:00+00:00
Record Updated At
2022-03-16
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Flumatinib", "Chronic Myeloid Leukemia, Chronic Phase", "Imatinib"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2022-03-16"
protocolSection.identificationModule.nctId
"NCT04677439"
protocolSection.identificationModule.officialTitle
"Efficacy and the Safety of Flumatinib in Treatment of CML-CP Patients With Ph+ Post Imatinib Failure"
protocolSection.statusModule.overallStatus
"UNKNOWN"
protocolSection.designModule.phases
["PHASE4"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Flumatinib (protocolSection.conditionsModule.conditions)
  • Chronic Myeloid Leukemia, Chronic Phase (protocolSection.conditionsModule.conditions)
  • Imatinib (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.